Figure 1.

Gilteritinib inhibits cell growth and induces apoptosis in CRC cells. A, The indicated CRC cell lines were treated with increasing concentrations of gilteritinib for 72 h. Cell viability was determined by MTS assay. B, Crystal violet results of HCT116 cells treated with gilteritinib at indicated concentration for 72 h. C, The indicated cell lines were treated with gilteritinib for 24 h at indicated concentrations. Apoptosis was analysed by Annexin V/PI staining followed by flow cytometry. D, The indicated cell lines were treated gilteritinib at indicated concentration. Caspase 3/7 activity was determined by fluorogenic analysis. E, The indicated cell lines were treated 50 nmol/L gilteritinib with or without 10 μmol/L z‐VAD‐fmk pre‐treatment. Apoptosis was analysed by Annexin V/PI staining followed by flow cytometry. F, HCT116 and SW480 cells were treated with 50 nmol/L gilteritinib at indicated time‐point. Cleaved caspase 3 and 9 were analysed by Western blotting. Results in (C), (D) and (E) were expressed as means ± SD of three independent experiments. **P < .01; *P < .05